Skip to content
20-F

Annual Report (Foreign)

Regencell Bioscience Holdings Limited RGC

0001213900-24-090791

← back to feed
Filed
Oct 25, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Jun 30, 2024 13.01M sh
Short Term Investments FY 2024 · Jun 30, 2023 $10M
Stockholders Equity FY 2024 · Jun 30, 2023 $12.03M
Current Liabilities FY 2024 · Jun 30, 2023 $606.91K
Total Liabilities FY 2024 · Jun 30, 2023 $632.32K
Current Assets FY 2024 · Jun 30, 2023 $11.62M
Total Assets FY 2024 · Jun 30, 2023 $12.62M
Shares Diluted FY 2024 · Jun 30, 2022 12.81M sh
Capex FY 2024 · Jun 30, 2022 $780.88K
Operating Cash Flow FY 2024 · Jun 30, 2022 −$5.27M
Eps Diluted FY 2024 · Jun 30, 2022 −$0.58
Eps Basic restated FY 2024 · Jun 30, 2022 −$0.58
Sga Expense FY 2024 · Jun 30, 2022 $5.08M
Rd Expense FY 2024 · Jun 30, 2022 $2.51M
Net Income FY 2024 · Jun 30, 2022 −$7.45M
Operating Income FY 2024 · Jun 30, 2022 −$7.62M